{"nctId":"NCT01600092","briefTitle":"A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)","startDateStruct":{"date":"2013-04-29","type":"ACTUAL"},"conditions":["Rotavirus Gastroenteritis"],"count":1020,"armGroups":[{"label":"RotaTeq™ Experimental Formulation","type":"EXPERIMENTAL","interventionNames":["Biological: RotaTeq™ experimental formulation"]},{"label":"RotaTeq™ Existing Formulation","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: RotaTeq™ existing formulation"]}],"interventions":[{"name":"RotaTeq™ experimental formulation","otherNames":["V260"]},{"name":"RotaTeq™ existing formulation","otherNames":["V260"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Parent or legal guardian agrees to have infant participate by giving written informed consent\n\nExclusion Criteria:\n\n* History of congenital abdominal disorders, prior rotavirus gastroenteritis, chronic diarrhea, failure to thrive, or abdominal surgery\n* History of intussusception\n* Known or suspected impairment of immunological function, including Severe\n\nCombined Immunodeficiency (SCID)\n\n* Prior administration of any rotavirus vaccine\n* Clinical evidence of active gastrointestinal illness, with the exception of well-controlled gastroesophageal reflux disease (GERD)\n* Receipt of 1) systemic corticosteroids (≥ 2mg/kg total daily dose of prednisone or equivalent) for 14 consecutive days or more since birth, or 2) systemic corticosteroids ≥ 2mg/kg/dose within 7 days prior to the administration of the first dose of study vaccine. Participant using non-systemic corticosteroids will be eligible for vaccination.\n* Residing in a household with an immunocompromised person\n* Prior receipt of a blood transfusion or blood products, including immunoglobulins\n* Participation in another interventional study within 14 days prior to the first study vaccination or expected anytime during the study\n* Receipt of investigational inactivated vaccines within 14 days or investigational live vaccines within 28 days prior to the first study vaccination or expected anytime during the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"12 Weeks","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer of Serum Neutralizing Antibody Response to Human Rotavirus Serotypes G1, G2, G3, G4, and P1A[8]","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"106.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"71.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.9","spread":null},{"groupId":"OG001","value":"90.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Tier-1 Adverse Events: Diarrhea, Vomiting, Elevated Temperature, and Irritability","description":"An adverse event is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse event. Protocol-defined Tier-1 adverse events to be collected up to 7 days after any vaccination were diarrhea, vomiting, elevated temperature (rectal \\>=38.1° C, \\>=100.5° F), and irritability.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"223","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Tier-1 Adverse Events: Intussusception","description":"The protocol-defined Tier-1 adverse event to be collected for the duration of the study (up to Day 185) was intussusception","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer of Serum Anti-Rotavirus Immunoglobulin A","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"240.5","spread":null},{"groupId":"OG001","value":"235.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With >=3-fold Rise From Baseline in GMT of Serum Neutralizing Antibody to Human Rotavirus Serotypes G1, G2, G3, G4, and P1A[8]","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null},{"groupId":"OG001","value":"26.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null},{"groupId":"OG001","value":"49.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":null},{"groupId":"OG001","value":"42.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":508},"commonTop":["Diarrhoea","Pyrexia","Vomiting","Nasopharyngitis","Upper respiratory tract infection"]}}}